Verve Therapeutics Stock Current Ratio
| VERV Stock | USD 5.77 0.13 2.20% |
Verve Therapeutics fundamentals help investors to digest information that contributes to Verve Therapeutics' financial success or failures. It also enables traders to predict the movement of Verve Stock. The fundamental analysis module provides a way to measure Verve Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Verve Therapeutics stock.
Verve |
Verve Therapeutics Company Current Ratio Analysis
Verve Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Verve Therapeutics Current Ratio | 11.55 X |
Most of Verve Therapeutics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Verve Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Verve Therapeutics has a Current Ratio of 11.55 times. This is 296.91% higher than that of the Biotechnology sector and 65.0% higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
Verve Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Verve Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Verve Therapeutics could also be used in its relative valuation, which is a method of valuing Verve Therapeutics by comparing valuation metrics of similar companies.Verve Therapeutics is currently under evaluation in current ratio category among its peers.
Verve Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Verve Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Verve Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Verve Fundamentals
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (8.29) % | ||||
| Current Valuation | 19.85 M | ||||
| Shares Outstanding | 84.66 M | ||||
| Shares Owned By Insiders | 5.28 % | ||||
| Shares Owned By Institutions | 97.86 % | ||||
| Number Of Shares Shorted | 15.97 M | ||||
| Price To Earning | 5.45 X | ||||
| Price To Book | 0.96 X | ||||
| Price To Sales | 20.02 X | ||||
| Revenue | 11.76 M | ||||
| Gross Profit | (128.15 M) | ||||
| EBITDA | (217.67 M) | ||||
| Net Income | (200.07 M) | ||||
| Cash And Equivalents | 293.56 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 74.91 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 11.55 X | ||||
| Book Value Per Share | 6.01 X | ||||
| Cash Flow From Operations | (149.55 M) | ||||
| Short Ratio | 11.25 X | ||||
| Earnings Per Share | (2.46) X | ||||
| Target Price | 26.2 | ||||
| Number Of Employees | 255 | ||||
| Beta | 1.76 | ||||
| Market Capitalization | 488.51 M | ||||
| Total Asset | 752.69 M | ||||
| Retained Earnings | (544.3 M) | ||||
| Working Capital | 600.94 M | ||||
| Net Asset | 752.69 M |
About Verve Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Verve Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verve Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verve Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.